Cipla, Glenmark get NPPA nod for inhaler pricing

The drug pricing regulator has allowed two Mumbai-based pharma majors – Cipla and Glenmark – to have an enhanced pricing for two of their respiratory (inhaler) products on grounds that these were innovative from the other similar products available in the market.

In a meeting in December, the National Pharmaceutical Pricing Authority’s (NPPA) expert committee decided to allow Cipla’s Synchrobreathe inhaler device a separate price other than the ceiling price already recommended by the regulator. Similarly, for Glenmark’s digital dose counter (sold under brand name Digihaler), the NPPA agreed to allow a different price.